Role of C-JUN terminal kinases (JNK1/2) in the development of cancer of the biliary tract
Cholangiocarcinoma (CCA) is an aggressive malignant bile duct cancer, and the second most common primary liver tumor In Europe, around 13,000 new CCA cases were diagnosed per year. However, the pathogenesis of CCA remains elusive and lack of diagnostic as well as treatment tools impede a better outc...
| Autor: | |
|---|---|
| Tipo de documento: | tese |
| Data de publicação: | 2021 |
| País: | España |
| Recursos: | Universidad Complutense de Madrid (UCM) |
| Repositório: | Docta Complutense |
| Idioma: | inglês |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/5483 |
| Acesso em linha: | https://hdl.handle.net/20.500.14352/5483 |
| Access Level: | Acceso aberto |
| Palavra-chave: | 616.361-006.04(043.2) Cancer of the biliary tract C-JUN terminal kinases (JNK1/2) Cáncer de vías biliares C-JUN cinasas N-terminales (JNK) Gastroenterología y hepatología Oncología 3205.03 Gastroenterología 3201.01 Oncología |
| Resumo: | Cholangiocarcinoma (CCA) is an aggressive malignant bile duct cancer, and the second most common primary liver tumor In Europe, around 13,000 new CCA cases were diagnosed per year. However, the pathogenesis of CCA remains elusive and lack of diagnostic as well as treatment tools impede a better outcome for patients. In the present study, we use a new animal model of CCA, to understand the molecular mechanism. In the present work, we hypothesize that the synergistic dysfunction of Jnk1 and Jnk2 in hepatocytes drives the development of cholangiocarcinogenesis. Mice with specific deletion of Jnk1/2 in hepatocytes (JnkΔhepa) and floxed (Jnkf/f) control mice were sacrificed at different time points during liver disease progression. Likewise, different toxicity treatments (i.e., TAA, DEN/TAA and DEN/CCl4) and experimental models were used... |
|---|